Anonymous
Guest
Anonymous
Guest
Bristol-Myers and AstraZeneca's other diabetes drug Onglyza has been a relative flop because it acts in the same way as Merck's (NYSE: MRK**) Januvia. Without any way to differentiate Onglyza, the companies have struggled to take a bite out of Januvia's market share.